Search research articles
Contact Us
Filters
Showing results (181-190 of 225) with videos related to
Page
of 23
Sort By:
Biochimica Et Biophysica Acta
|
October 4, 2016
Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma
Ashley L Hilchie, Andrew J Sharon, Evan F Haney, et al.
Plos One
|
April 30, 2013
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil
Jennifer I Hare, Robert W Neijzen, Malathi Anantha, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 21, 1998
Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection
L Embree, K A Gelmon, A W Tolcher, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
November 4, 2015
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma
M Verreault, M Wehbe, D Strutt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 15, 2017
Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity
Alireza Baradaran-Heravi, Jürgen Niesser, Aruna D Balgi, et al.
Drug Delivery and Translational Research
|
September 5, 2019
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use
Kent T J Chen, Malathi Anantha, Ada W Y Leung, et al.
Breast Cancer Research and Treatment
|
March 10, 2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
Wieslawa H Dragowska, Maïté Verreault, Donald T T Yapp, et al.
Molecular Cancer Therapeutics
|
August 8, 2006
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
Lawrence D Mayer, Troy O Harasym, Paul G Tardi, et al.
Biochimica Et Biophysica Acta
|
February 18, 2004
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol
Nancy Dos Santos, Kelly A Cox, Cheryl A McKenzie, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 8, 2022
DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation
Ada W Y Leung, Kent T J Chen, Gemma M Ryan, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 225) with videos related to
Sort By:
Page
of 23
Biochimica Et Biophysica Acta
|
October 4, 2016
Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma
Ashley L Hilchie, Andrew J Sharon, Evan F Haney, et al.
Plos One
|
April 30, 2013
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil
Jennifer I Hare, Robert W Neijzen, Malathi Anantha, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 21, 1998
Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection
L Embree, K A Gelmon, A W Tolcher, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
November 4, 2015
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma
M Verreault, M Wehbe, D Strutt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 15, 2017
Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity
Alireza Baradaran-Heravi, Jürgen Niesser, Aruna D Balgi, et al.
Drug Delivery and Translational Research
|
September 5, 2019
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use
Kent T J Chen, Malathi Anantha, Ada W Y Leung, et al.
Breast Cancer Research and Treatment
|
March 10, 2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
Wieslawa H Dragowska, Maïté Verreault, Donald T T Yapp, et al.
Molecular Cancer Therapeutics
|
August 8, 2006
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
Lawrence D Mayer, Troy O Harasym, Paul G Tardi, et al.
Biochimica Et Biophysica Acta
|
February 18, 2004
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol
Nancy Dos Santos, Kelly A Cox, Cheryl A McKenzie, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 8, 2022
DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation
Ada W Y Leung, Kent T J Chen, Gemma M Ryan, et al.
Page
of 23